The University of Kansas Cancer Center, through a partnership with Notable Labs, will conduct the first clinical trial for a potentially groundbreaking blood cancer drug by the end of this year.
Notable Labs, a startup that accelerates drug development by matching drugs with patients who are most likely to respond, donated the commercial rights to price, manufacture and distribute ND-1000 for pediatric leukemia to Chicago-based nonprofit, Cures Within Reach, according to a release.
